Assessment of solid tumor burden
The present disclosure is directed toward measurement of expression of one or both of an activating Natural Killer (NK) cell receptor and its ligand(s) on peripheral blood cells as a means to assess solid tumor burden. In particular, the present disclosure provides tools for assessing cancer recurrence or risk thereof following reduction of a solid tumor, and for developing a treatment regime for a cancer patient.
1. A method for assessing recurrence of and treating glioblastoma multiforme (GBM) in a cancer patient having had GBM, said method comprising:
a) obtaining a post-treatment blood sample from said patient;
b) subjecting said post-treatment blood sample from said patient to an antibody based technique for quantitation of expression of a membrane-associated form of at least one NKG2D ligand on myeloid cells of the sample, wherein the at least one NKG2D ligand comprises ULBP1;
c) diagnosing said patient with recurrence of said GBM when an elevated level of expression of the at least one NKG2D ligand in said post-treatment blood sample is detected as compared to a control blood sample; and
d) administering one or both of chemotherapy and radiation to said patient diagnosed with recurrence of said GBM.
2. The method of claim 1 , wherein the at least one NKG2D ligand further comprises one or both of MICA and MICB.
3. The method of claim 1 , wherein the post-treatment blood sample and the control blood sample each comprise peripheral blood lymphocytes isolated by ficoll centrifugation.
4. The method of claim 1 , wherein said control blood sample is a blood sample from a tumor free subject, or from said patient at a time when burden of said GBM is known to be minimal.
5. The method of claim 1 , wherein said elevated level of expression is detected on CD11b-positive myeloid cells.
6. The method of claim 5 , wherein said myeloid cells express one or both of CD45 and MHC class II.
7. A method for assessing prognosis of and treating glioblastoma multiforme (GBM) a cancer patient having GBM, said method comprising:
a) obtaining a pre-treatment blood sample from said patient; and
b) subjecting said pre-treatment blood sample from said patient to an antibody based technique for quantitation of expression of a membrane-associated form of at least one NKG2D ligand on myeloid cells of the sample, wherein the at least one NKG2D ligand comprises ULBP1;
c) determining said patient has a poor prognosis when an elevated level of expression of the at least one NKG2D ligand in said pre-treatment blood sample is detected as compared to a control blood sample from a healthy subject; and
d) adopting an aggressive treatment regimen for said patient determined to have a poor prognosis, wherein said aggressive treatment regimen involves one or more of surgery, chemotherapy and radiation.
8. The method of claim 7 , wherein the at least one NKG2D ligand further comprises one or both of MICA and MICB.
9. The method of claim 7 , wherein the pre-treatment blood sample and the control blood sample each comprise peripheral blood lymphocytes isolated by ficoll centrifugation.
10. The method of claim 7 , wherein said elevated level of expression is detected on CD11b-positive myeloid cells.
11. The method of claim 7 , wherein said myeloid cells express one or both of CD45 and MHC class II.
12. The method of claim 6 , wherein the myeloid cells express MHC class II and the MHC class II is HLA-DR.
13. The method of claim 11 , wherein the myeloid cells express MHC class II and the MHC class II is HLA-DR.
14. The method of claim 1 , wherein the antibody based technique comprises flow cytometry.
15. The method of claim 7 , wherein the antibody based technique comprises flow cytometry.
16. method of claim 1 , wherein the post-treatment blood sample is obtained from the patient at least one month after resection of the GBM.
17. The method of claim 7 , wherein the pre-treatment blood sample is obtained from the patient prior to resection of the GBM.